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COMMENTARY

Complement factor H and the hemolytic
uremic syndrome
John P. Atkinson and Timothy H.J. Goodship

Types of HUS

HUS and thrombotic thrombocytopenia purpura (TTP) constitute a group
of diseases known as thrombotic microangiopathies in which organ damage results from platelet aggregation and fibrin
plugs in small vessels. HUS, in particular, is
characterized by microangiopathic hemolytic anemia (damage to red blood cells as
they travel through narrowed capillaries),
consumptive thrombocytopenia (exhaustion of platelets as they become enmeshed
in platelet-fibrin thrombi), and microvascular glomerular thrombosis (formation of
thrombi in the kidney).The thrombotic
microangiopathy is particularly severe
in the renal microvasculature and leads
to acute renal failure. TTP shares these
features, but neurologic dysfunction dominates the clinical presentation. Patients
with TTP carry mutations in the metalloproteinase ADAMTS13 or have autoantibodies against this metalloproteinase,
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allowing for an etiologic distinction between TTP and HUS.
The most common form of HUS is
associated with a diarrheal illness caused
by infection with strains of Escherichia coli
that produce Shiga-like toxins (Stx-1 and
Stx-2) and hence is called Stx-HUS or
diarrhea-positive HUS. Less common is
atypical HUS (aHUS) in which there is
no preceding diarrhea (nonenteropathic
HUS). Precipitating factors commonly
implicated in the pathogenesis of aHUS
include infections, use of endothelialdamaging drugs, malignancies, transplantation, and pregnancy.These triggers can
all cause endothelial cell activation and
injury. Although there is some pathophysiologic overlap, Stx-HUS–induced
pathology is predominant in the glomerulus, whereas the predominant pathology in aHUS involves the renal
and interlobular arterioles. The prognosis of Stx-HUS is favorable, with the
majority of patients recovering renal
function, whereas in aHUS there is 25%
acute mortality and most of the survivors develop end-stage renal disease.
Familial occurrence of aHUS has
been recognized for many years (1). Inheritance was thought to be predominantly recessive, but it is now recognized
that most families feature dominant in-
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heritance with 50% penetrance. In
1998, Warwicker et al. (2) published the
results of a linkage study in three families
with aHUS. This pivotal study showed
segregation of the disease to the q32
region of chromosome 1, which contains
genes that regulate complement activation. A possible link between complement
abnormalities and aHUS had also been
recognized for many years. One study in
particular showed that low levels of the
complement protein C3 and glomerular
deposition of C3 fragments were associated with disease (3). However, these
clinical reports were not widely appreciated, as most patients had normal levels
of circulating complement. And a role
for innate immunity was not considered.
aHUS mutations have since been
described in the genes encoding five
complement proteins, including FH,
membrane cofactor protein/CD46
(MCP), factor I (FI), factor B (FB), and
C3 (4–8). Functional studies have shown
that the mutations in the three regulators FH, FI, and MCP lead to loss of
function and thus more complement
activation, whereas the mutations in FB
are gain of function. This has provided
unequivocal evidence that complement
dysregulation is involved in the pathology
of aHUS. With this knowledge in hand,
Pickering et al. (9) have now developed
a faithful model of human aHUS in an
FH-deficient mouse. The new mouse
model, described in this issue (p. 1249),
is sufficiently “human-like” so that key
questions related to immune pathogenesis can now be addressed and potential
therapeutic interventions assessed.
Alternative pathway of complement
activation

The complement system (as one of our
students recently informed us) is “a
simple little proteolytic cascade when
compared with cytokine biology and
signal transduction pathways.” It is an
1245
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Immune recognition is coupled to powerful proinflammatory effector pathways
that must be tightly regulated. The ancient alternative pathway of complement
activation is one such proinflammatory pathway. Genetic susceptibility factors
have been identified in both regulators and activating components of the alternative pathway that are associated with thrombotic microangiopathies, glomerulonephritides, and chronic conditions featuring debris deposition. These
observations indicate that excessive alternative pathway activation promotes
thrombosis in the microvasculature and tissue damage during debris accumulation. Intriguingly, distinct genetic changes in factor H (FH), a key regulator of
the alternative pathway, are associated with hemolytic uremic syndrome (HUS),
membranoproliferative glomerulonephritis (dense deposit disease), or age-related
macular degeneration (AMD). A mouse model of HUS designed to mirror human
mutations in FH has now been developed, providing new understanding of the
molecular pathogenesis of complement-related endothelial disorders.
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FH

The first candidate gene in the regulators of complement activation (RCA)
cluster that was linked to aHUS was FH,

a complement control protein (CCP)
that protects host tissue from complement attack (2, 4). The surfaces of
“foreign” particles, such as viruses and
bacteria, are vulnerable to complement
activity, as they lack FH and other complement regulatory proteins. FH regulates the feedback loop in three ways. It
is a cofactor for the serine protease FI,
which cleaves C3b. This cleavage reaction produces a fragment, iC3b, which
has no hemolytic or amplification potential (Fig. 1 B). Second, FH both
prevents the formation of and accelerates the disassociation of the alternative
pathway C3 convertase, C3bBb. Finally,
FH binds to polyanions on host cell
surfaces and tissue matrices, such as basement membranes, thus blocking deposition of C3b. FH and other proteins
within the RCA cluster share a common
structural motif consisting of contiguous, homologous, independently folding
modules called short consensus repeats
or CCP modules. FH consists of 20 such
repeats of 60 amino acids each that
are held together by short 2– to 6–amino
acid linkers.
Previous reports had shown a possible
association between aHUS and reduced
plasma concentrations of FH (10, 11).
Mutations in the FH gene in aHUS
patients have now been widely described.
The interactive FH-HUS mutation database (http://www.FH-HUS.org) lists 71

Figure 1. Activation and inactivation of the alternative complement pathway. (A) C3b binds
FB, which is then converted to Bb, by the serine protease factor D (not depicted). The resulting C3bBb
is the alternative pathway C3 convertase that cleaves additional C3 to C3b, thus amplifying the
process. Properdin stabilizes this convertase (not depicted). (B) This process is controlled by regulatory
proteins such as FH. It decays Bb from C3b and is a cofactor for degradation of C3b to iC3b by the
serine protease FI. FH attaches to surfaces through its heparin/anionic-binding sites in its carboxylterminus (CCPs 16–20) while the decay-accelerating activity and cofactor activity sites are at the
amino terminus (CCPs 1–4).
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disease-associated mutations (12). These
are present in 30% of patients, including those with sporadic and familial forms
of the disease. The majority are heterozygous missense mutations that cluster
in the carboxyl-terminal exons and are
associated with normal levels of circulating FH. The remaining mutations are
mostly heterozygous deletions or missense mutations that result in either a
truncated protein or impaired secretion
of the protein and thus cause a 50%
reduction in plasma levels of FH.
This clustering of missense mutations in the C-terminal region, which is
crucial for FH binding to host surfaces,
is remarkable. Functional and structural
studies of mutants indicate that the reduced interaction between FH and cell
surfaces leads to inefficient cofactor
activity (12).
There are two existing animal models
of total FH deficiency: the Norwegian
Yorkshire pig (13) and a knockout mouse
model (14). In both, the deficient animals
develop membranoproliferative glomerulonephritis rather than HUS. This form
of glomerulonephritis is similar to the
disease seen in humans with homozygous
FH deficiency in which dense deposits
of C3 fragments accumulate in the glomerulus (15).This illness can present in a
variety of ways, including asymptomatic urinary abnormalities, nephrotic
syndrome, and chronic kidney disease.
Patients with membranoproliferative glomerulonephritis also develop ocular lesions similar to those seen in AMD. A
series of studies has shown that polymorphisms in the FH gene are associated
with increased susceptibility to AMD
(16–19). In particular, a polymorphism
in exon 9 (rs1061107:1277T>C) that
results in a tyrosine to histidine change
(Y402H) in the seventh CCP, has been
shown to be a susceptibility factor in all
these studies.
A murine model of aHUS

In this issue, Pickering et al. describe a
mouse model of aHUS in which the disease is remarkably similar to that seen in
human patients. Taking advantage of the
FH−/− mouse they had previously developed (14), the group produced a transgenic mouse in which the FH gene lacks
MOUSE MODEL OF HUS | Atkinson and Goodship
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ancient innate immune network of plasma
proteins that began evolutionarily as a
host defense system of hemolymph. The
goal of the oldest cascade, the alternative
pathway, is to rapidly coat invading
microbes with large quantities of the
opsonic complement fragment C3b
(Fig. 1 A). This process is facilitated by
a feedback or amplification loop that
allows several million molecules of C3b
to be deposited on bacteria within a few
seconds. Complement activation also
occurs, albeit usually in a more limited
fashion, on altered self-tissue, such as on
cells undergoing apoptosis and at sites of
injury and infection. To prevent the
accumulation of undesirable quantities
of deposited C3b, the host synthesizes a
family of regulatory proteins that inhibit
the feedback loop both on cell surfaces
and in plasma. These regulatory proteins
are particularly designed to prevent C3
activation, and heterozygous mutations
(haploinsufficiency) in these regulators
predispose humans to aHUS. In individuals carrying these mutations, expression
of even 50% of normal levels of these
inhibitors is inadequate to prevent disease at times of injury and stress in the
renal microvasculature.
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Other complement proteins implicated
in HUS

In the second of the original three
families reported by Warwicker et al.,
a mutation in MCP was identified (5).
Screening of multiple cohorts established that 15% of patients with aHUS
JEM VOL. 204, June 11, 2007

have a mutation (usually heterozygous) in
the MCP gene (12). MCP is expressed by
most cells and, like FH, acts as a cofactor
for the inactivation of C3b. The activity
of MCP is intrinsic, meaning that it only
has cofactor activity for C3b when it is
bound to the same cell (20). An analysis
of the initial 25 MCP mutations in aHUS
patients has recently been reported (21).
Mutations in FI, the protease required
for C3b cofactor activity, also predispose to aHUS. Heterozygous changes
in FI account for 5% of the known
mutations in aHUS (6, 22). FI is a disulphide-linked, two-chain serine protease
consisting of a 55-kD heavy chain and
a catalytic 38-kD light chain. FI cleaves
C3b but only if C3b is associated with
a cofactor protein such as FH or MCP
(Fig. 1 B; reference 22).
Mutations in FB were also recently
described in two families (7). One mutation stabilized the alternative pathway
C3 convertase by increasing the affinity
of the interaction between FB and C3b.
The other mutation made the C3bBb
enzyme complex more resistant to decay.
Both mutations resulted in increased
activation of the alternative pathway.
Mutations in C3 itself have also been
described in a select group of aHUS
patients with low C3 concentrations in
their plasma but without mutations in
FH, MCP, FI, or FB (8).
Immunopathogenesis of HUS

These analyses of aHUS-causing mutations in complement proteins establish
several points of interest. First, although
FH and MCP both harbor cofactor
activity for FI, they do not have overlapping activity, as mutations in either
protein predispose to disease in the renal microvasculature. It is also clear that
half the normal levels of FH, MCP, or
FI is not sufficient to protect the renal
endothelium after injury (i.e., there is an
evolutionary reason why these proteins
are maintained at a certain level and not
50% less). In addition, anionic (heparin)binding sites are required for FH to
efficiently bind to damaged cells, exposed tissue matrices, and the basement
membrane, and thus to prevent a thrombomicroangiopathy. It is noteworthy that
the above insights came about by screen-

ing the human genome in multiplex
families. The common theme that
emerges relative to the specific functional deficiency in these complement
regulators is a decrease in overall cofactor activity for C3b.
We hypothesize that Stx-HUS also
follows the same sequence of events.The
major difference between the Stx-HUS
and aHUS may be secondary to the degree or type of damage to the endothelium required to cause disease. Less injury
may be sufficient to cause aHUS in individuals with predisposing mutations, such
as those in FH. A more severe degree of
injury, such as that caused by Shiga toxins, may be required for HUS associated
with E. coli epidemics. However, it is
important to note that only 10–15% of
patients in these epidemics develop HUS
(23). Minor variations in the expression
levels or functional activity of one or
more members of the alternative pathway may be one explanation for this
finding. We recently identified a young
girl with a heterozygous mutation in
MCP who developed Stx-HUS. E. coli
O157:H7 was isolated from her stool,
and Shiga toxin was identified in her
blood and stool. The patient died 4 days
after presentation. At autopsy, she had
multiorgan failure secondary to a diffuse
microthromboangiopathy. This informative case illustrates the interplay between
a predisposing regulatory protein deficiency and the potency of the trigger in
the pathogenesis of HUS.
We still have much to learn about the
interplay among endothelial injury/stress,
complement activation, and thrombosis
in the microvasculature. The “Pickering
model” of aHUS will allow many questions to be addressed. What, for example,
is the nature of the damage induced
by bacterial toxins and other triggers?
Which parts of the complement activation cascade (opsonins, anaphylotoxins,
membrane attack complex) induce
thrombosis? How do the complement
and clotting systems interact, and what
is unique about the kidney microvasculature? This field of investigation was
broken open by analyzing a few families
using whole genome screens. Based on
these findings, a mouse model has now
been developed that can be used to
1247
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the exons encoding the five C-terminal
CCP modules. As noted above, in humans
with FH-associated aHUS, a majority of
the mutations occur in these C-terminal
repeats and disrupt a heparin-binding site.
Homozygous FH-deficient mice
have very low circulating levels of C3 and
FB because these proteins are consumed
as a result of excessive complement activation. Consequently, these mice have
minimal complement-activating capacity.
By introducing the C-terminal truncation of FH into the FH knockout animals, Pickering et al. restored the control
of complement activation in the fluid
phase. As a result, the mice did not develop glomerulonephritis, and their circulating levels of C3b and FB were
partially restored. The combination of
functional alternative pathway activation
coupled with a deficiency in the capacity
of FH to bind anionic targets led to spontaneous aHUS in mice homozygous for
the transgene (Cfh−/−.FH∆16-20). Many
parameters of disease in the mice, including the hematologic abnormalities and
glomerular pathology, closely resembled
human aHUS. Of note, however, the
mice heterozygous for expression of the
mutated FH (Cfh+/−.FH∆16-20; i.e.,
50% of FH carrying the deletion of CCPs
16–20 and 50% WT FH), which most
closely resembles the situation in humans,
did not develop aHUS. As Pickering et al.
comment, it is becoming apparent that
aHUS in humans is not a straightforward
monogenic disease, but rather a disease in
which mutations may be found in more
than one complement gene in an individual patient.Thus, such mutations must
be considered to be predisposing rather
than causative, as a triggering factor is
necessary to initiate the disease (12). This
murine model of aHUS affords a unique
opportunity to resolve some of the conundrums of aHUS. The model will also
facilitate testing of novel therapies, such as
targeted complement inhibitors.
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address outstanding questions about
the pathogenesis and treatment of this
complex human disease.
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